GK
Gujarat Kidney & Super Speciality Ltd (GKSL)
₹149.28
Mkt cap
₹1,261 Cr
P/E ratio
66.40
P/B
4.47
Div yield
0.00%
ROE
11.10%
ROCE
14.50%
EPS (TTM)
₹2.25
Book value
₹33
52W range
98–210
Sector
Healthcare
Price history
Previous close
Incorporated in 2019, Gujarat Kidney and Super Speciality Limited specializes in providing multispeciality healthcare services. [1]
NSE GKSLBSE 544666
Health check
Constructive
ValuationFair
ProfitabilityAverage
GrowthHigh
TechnicalsNeutral
52-week range
−28.85% from high₹149
₹98+51.77% from low₹210
Current
₹149.28
Prev close
₹150.55
Day
−0.84%
Price performance
1D
−1.36%
1W
−4.61%
1M
−17.25%
3M
−5.05%
6M
+6.47%
1Y
—
YTD
+45.34%
Financials
Revenue, profit & margin
P/E ratio
66.4×
GKSL is 30% above the sector median of 51.1×
GKSL66.4×
Sector median51.1×
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 9.41 | 11.79 | 9.78 | 15.26 | 12.93 | 23.25 | 30.58 | 34.29 | 38.09 | |
| YoY Sales growth | +37.41% | +97.20% | +212.68% | +124.71% | +194.59% | |||||
| Expenses | 4.55 | 7.19 | 7.17 | 6.64 | 7.81 | 16.35 | 24.28 | 25.92 | 27.88 | |
| Operating Profit | 4.86 | 4.60 | 2.61 | 8.62 | 5.12 | 6.90 | 6.30 | 8.37 | 10.21 | |
| OPM % | 51.65% | 39.02% | 26.69% | 56.49% | 39.60% | 29.68% | 20.60% | 24.41% | 26.80% | |
| Other Income | 0.04 | 0.05 | 0.05 | 0.01 | 0.09 | 0.06 | 0.71 | 0.69 | 0.59 | |
| Interest | 0.16 | 0.17 | 0.16 | 0.18 | 0.28 | 0.60 | 0.82 | 0.66 | 0.66 | |
| Depreciation | 0.74 | 0.88 | 0.90 | 0.96 | 0.90 | 1.33 | 1.51 | 1.44 | 1.52 | |
| Profit before tax | 4.00 | 3.60 | 1.60 | 7.49 | 4.03 | 5.03 | 4.68 | 6.96 | 8.62 | |
| Tax % | 26.25% | 29.72% | 16.88% | 27.77% | 28.54% | 26.44% | -2.99% | 23.56% | 23.55% | |
| Net Profit | 2.96 | 2.53 | 1.34 | 5.40 | 2.88 | 3.70 | 4.82 | 5.32 | 6.60 | |
| EPS in Rs | 0.52 | 0.44 | 0.23 | 0.85 | 0.47 | 0.37 | 0.64 | 0.66 | 0.74 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202671.45%Promoter
Promoters71.45%
FIIs6.52%1.63
DIIs0.25%0.31
Public21.77%1.33
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Apollo Hospitals | ₹8,712.50 | 55.34 | 1,25,272 | 0.23% | 660 | +30.04% | 7,615 | +23.04% | 17.45% |
| Max Healthcare | ₹1,030.90 | 70.64 | 1,00,340 | 0.19% | 414 | −15.54% | 2,569 | +20.31% | 14.71% |
| Manipal Health | ₹701.95 | 98.46 | 92,333 | 0.00% | 285 | +10.29% | 3,399 | +37.32% | 12.10% |
| Aster DM Quality | ₹737.95 | 122.71 | 64,325 | 0.41% | 322 | +148.12% | 2,829 | +136.32% | 11.57% |
| Fortis Health. | ₹806.80 | 56.77 | 60,910 | 0.12% | 320 | +2.01% | 2,735 | +17.30% | 13.45% |
| Narayana Hrudaya | ₹1,907.60 | 43.08 | 38,984 | 0.24% | 301 | +16.61% | 2,844 | +73.01% | 15.50% |
| Global Health | ₹1,444.20 | 59.98 | 38,831 | 0.03% | 219 | +51.38% | 1,469 | +33.64% | 17.37% |
| Gujarat Kidney | ₹159.90 | 66.35 | 1,261 | 0.00% | 7 | +118.73% | 38 | +194.59% | 14.48% |
| Median: 31 Co. | ₹508.20 | 51.09 | 7,212 | 0.00% | 40 | +22.67% | 431 | +22.77% | 14.62% |
Filings
Annual reports1
Concall transcripts4
Announcements5
Announcement under Regulation 30 (LODR)-Earnings Call Transcript 11 NovAnnouncement under Regulation 30 (LODR)-Newspaper Publication 5 Nov - Newspaper publication for Unaudited Financial Statements for the Quarter ended September 2026.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 5 Nov - Audio recording of Q2 FY27 earnings call uploaded on November 5, 2026.Announcement under Regulation 30 (LODR)-Investor Presentation 5 NovAnnouncement under Regulation 30 (LODR)-Investor Presentation 4 Nov - Investor Presentation for scheduled Conference Call on November 05, 2026





